Experimental pharmacology is the basis of drug discovery. The discovery of novel drugs can be done through the identification of active ingredients in traditional medicines or via searching chemical libraries for specific molecules with predicted kinetic properties. The aim of the Research Topic was to throw light on recent pharmacological advancements in managing non-communicable diseases.
The Research Topic provides insight into the evaluation of mirabegron, which is a β3-adrenergic agonist used as a medical expulsive therapy for ureteral stones in adults. One study concluded with the opinion that mirabegron appeared to a better treatment option than a placebo for stones ≤4–6 mm, especially distal ureteral stones.
Catheter-related bladder discomfort (CRBD) secondary to the use of large-diameter urinary catheters, particularly after urological surgeries, can lead to increased frequency in urination, sometimes accompanied by involuntary loss of urine. Nefopam, a centrally acting analgesic with anticholinergic properties, was evaluated for management of postoperative CRBD. Nefopam administration mitigated the frequency and severity of early postoperative CRBD without causing evident side effects.
Ondansetron was validated for its use in pregnancy-associated morning sickness, but the study lacked clarity in the identification and analysis of efficacy and safety. Similarly, ondansetron has been a gold standard in treating chemotherapy-induced nausea and vomiting. However, there is still room to improve safety and the quality of patient’s lives.
Amphetamine and its derivatives have been employed in the treatment of attention-deficit hyperactive syndrome for a long time. A study emphasized the importance of recognizing potential side effects and addiction risks for this drug.
Tyrosine kinase inhibitors are one of the mainstays in cancer therapy and were proposed to have glycemic control properties. The results of a study showed a mixture of improved glycemic control with some tyrosine kinase inhibitors but clinically insignificant hyperglycemia control with other tyrosine kinase inhibitors. The repurposing strategies of these inhibitors towards managing diabetes mellitus needs further exploration.
Statements
Author contributions
AS: Writing–original draft, Writing–review and editing, Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization. VF-M: Writing–original draft, Writing–review and editing, Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization. HA: Writing–review and editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
experimental pharmacology, experimental pharmacology and drug discovery, adrenergy agonist, chemotherapy, hyperactive syndrome
Citation
Sharif A, Flores-Morales V and Aly HF (2025) Editorial: Reviews in experimental pharmacology and drug discovery 2023: pharmacological management of non-communicable diseases. Front. Pharmacol. 16:1435638. doi: 10.3389/fphar.2025.1435638
Received
20 May 2024
Accepted
10 March 2025
Published
01 April 2025
Volume
16 - 2025
Edited and reviewed by
Heike Wulff, University of California, Davis, United States
Updates
Copyright
© 2025 Sharif, Flores-Morales and Aly.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ali Sharif, alisharif.pharmacist@gmail.com; Virginia Flores-Morales, virginia.flores@uaz.edu.mx
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.